Access to anti-retroviral drugs, male in World

World: Access to anti-retroviral drugs, male was 73.0% in 2024. ◆ Volatile

Latest (2024)
73.0%
Change on year
up 4.3%
Rank
15th
of 19 groups
All-time high
73.0%
in 2024
All-time low
2.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in World, 2000–2024

0204060802000201220242000: 2 %2001: 2 %2002: 3 %2003: 3 %2004: 4 %2005: 6 %2006: 8 %2007: 11 %2008: 14 %2009: 18 %2010: 24 %2011: 27 %2012: 30 %2013: 34 %2014: 38 %2015: 42 %2016: 46 %2017: 51 %2018: 55 %2019: 59 %2020: 62 %2021: 65 %2022: 68 %2023: 70 %2024: 73 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in World stood at 73.0%. That is the highest value across all 25 years on record.

The figure is up 4.3% on the previous year and up 92.1% over ten years.

Over the whole period, access to anti-retroviral drugs, male in World peaked at 73.0% in 2024 and was at its lowest, 2.0%, in 2000.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in World, year by year

Annual values for Access to anti-retroviral drugs, male (%) in World, 2000 to 2024.
Year % Change
2000 2.0%
2001 2.0% +0.0%
2002 3.0% +50.0%
2003 3.0% +0.0%
2004 4.0% +33.3%
2005 6.0% +50.0%
2006 8.0% +33.3%
2007 11.0% +37.5%
2008 14.0% +27.3%
2009 18.0% +28.6%
2010 24.0% +33.3%
2011 27.0% +12.5%
2012 30.0% +11.1%
2013 34.0% +13.3%
2014 38.0% +11.8%
2015 42.0% +10.5%
2016 46.0% +9.5%
2017 51.0% +10.9%
2018 55.0% +7.8%
2019 59.0% +7.3%
2020 62.0% +5.1%
2021 65.0% +4.8%
2022 68.0% +4.6%
2023 70.0% +2.9%
2024 73.0% +4.3%

Averages by decade

DecadeAverage LowestHighest Years
2000s 7.1% 2.0% 18.0% 10
2010s 40.6% 24.0% 59.0% 10
2020s 67.6% 62.0% 73.0% 5

Countries ranked near World

  1. 12 Spain 91.0% compare
  2. 13 Burundi 90.0% compare
  3. 13 Malawi 90.0% compare
  4. 13 Namibia 90.0% compare
  5. 13 Switzerland 90.0% compare
  6. 17 France 89.0% compare
  7. 17 Iceland 89.0% compare
  8. 17 Ireland 89.0% compare
  9. 17 Netherlands 89.0% compare
  10. 17 Romania 89.0% compare
  11. 17 Zimbabwe 89.0% compare

See the full ranking of 160 places →

More gender data for World

All data for World →

Frequently asked questions

What is access to anti-retroviral drugs, male in World?
Access to anti-retroviral drugs, male in World was 73.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in World?
The highest recorded value was 73.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in World?
The lowest recorded value was 2.0% in 2000.
How does World rank for access to anti-retroviral drugs, male?
World ranks 15th out of 19 groups with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in World?
Over the last ten years it is up 92.1%. The long-run trend across the full record is volatile.
Where does this World data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in World. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/world/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/world/">Access to anti-retroviral drugs, male in World</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.